Among other ADCs targeting CD79B (Table 2) [105, 106], iladatuzumab vedotin evaluated alone or in combination with rituximab in a phase I study in patients with R/R B cell lymphomas or chronic lymphocytic leukemia (CLL) demonstrated an unsatisfactory ORR and safety profile that hindered its progress into phase II trials (NCT02453087) [107]. This evidence concerns the gene CD79B and B-cell chronic lymphocytic leukemia.